Authors
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Jörg T Hartmann, Daniel Pink, Jochen Schütte, Giuliano Ramadori, Peter Hohenberger, Justus Duyster, Salah-Eddin Al-Batran, Marcus Schlemmer, Sebastian Bauer, Eva Wardelmann, Maarit Sarlomo-Rikala, Bengt Nilsson, Harri Sihto, Odd R Monge, Petri Bono, Raija Kallio, Aki Vehtari, Mika Leinonen, Thor Alvegård, Peter Reichardt
Publication date
2012/3/28
Journal
Jama
Volume
307
Issue
12
Pages
1265-1272
Publisher
American Medical Association
Description
Context
Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared with placebo.
Objective
To investigate the role of imatinib administration duration as adjuvant treatment of patients who have a high estimated risk for GIST recurrence after surgery.
Design, Setting, and Patients
Patients with KIT-positive GIST removed at surgery were entered between February 2004 and September 2008 to this randomized, open-label phase 3 study conducted in 24 hospitals in Finland, Germany, Norway, and Sweden. The risk of GIST recurrence was estimated using the modified National Institutes of Health Consensus Criteria.
Intervention
Imatinib, 400 mg per day, orally for either 12 months or 36 months, started within 12 weeks of surgery.
Main Outcome Measures
The primary end point was RFS; the secondary end …
Total citations
Scholar articles
H Joensuu, M Eriksson, KS Hall, JT Hartmann, D Pink… - Jama, 2012